Impact of Semaglutide and Safinamide versus Bromocriptine on Parkinsonism induced in rats | ||
| Benha Medical Journal | ||
| Articles in Press, Accepted Manuscript, Available Online from 17 October 2025 PDF (1.48 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/bmfj.2025.388219.2438 | ||
| Authors | ||
| Mohamed E. Mansour1; Rezk A. Sanad2; Mary E. Yacoub3; Sara A. Mosa* 4; Salwa A. Elgendy5 | ||
| 1Professor of clinical Pharmacology, Faculty of Medicine, Benha University | ||
| 2Professor of clinical Pharmacology,Faculty of Medicine, Benha University | ||
| 3Ass.Prof. of clinical Pharmacology, Faculty of Medicine, Benha University | ||
| 4MSc, M.B.B.Ch, Faculty of Medicine, Benha University | ||
| 5Assistant Professor of clinical Pharmacology, Faculty of Medicine, Benha University | ||
| Abstract | ||
| Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by motor impairments such as bradykinesia, rigidity, tremors, and postural instability. Oxidative stress, neuroinflammation, and dopaminergic neuronal loss are key pathological features. Aim: This study aimed to evaluate and compare the neuroprotective effects of semaglutide and safinamide against bromocriptine in a rat model of PD. Materials and Methods: Parkinsonism was induced in rats using rotenone. Animals were divided into eight groups: control, DMSO, bromocriptine (2.5 mg/kg), semaglutide (0.62 mg/kg), safinamide (10 mg/kg), and their respective combinations. Biochemical assays were performed to measure malondialdehyde (MDA), glutathione (GSH), and dopamine levels. Inflammatory cytokines (TNF-α, IL-6) were analyzed. Behavioral tests assessed motor function. Histopathological and immunohistochemical evaluations, including caspase-3 expression, were conducted. Results: All treated groups showed significant improvements in oxidative stress parameters, dopamine restoration, and inflammatory cytokine reduction. Behavioral performance improved across all drug-treated groups, with combined therapies yielding superior outcomes. The bromocriptine + safinamide group exhibited the greatest neuroprotective and functional recovery effects. Conclusion: Bromocriptine, semaglutide, and safinamide, either alone or in combination, demonstrated therapeutic efficacy in rotenone-induced Parkinsonism in rats. Combination therapies, particularly bromocriptine + safinamide, showed enhanced neuroprotective benefits, suggesting a promising strategy for PD management. | ||
| Keywords | ||
| Parkinsonism; Bromocriptine; Semaglutide; Safinamide | ||
|
Statistics Article View: 4 PDF Download: 3 |
||
